Answers are grounded in this paper and cite their sources.
// Ninh B. Doan 1, 2 , Ha S. Nguyen 2 , Andrew Montoure 2 , Mona M. Al-Gizawiy 3 , Wade M. Mueller 2 , Shekar Kurpad 2 , Scott D. Rand 3 , Jennifer M. Connelly 4 , Christopher R. Chitambar 4 , Kathleen M. Schmainda 3, 6 , Shama P. Mirza 1, 7, 8 1 Biotechnology and Bioengineering Center, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 2 Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 3 Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 4 Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 5 Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 6 Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 7 Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 8 Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, Wisconsin, 53211, USA Correspondence to: Ninh B. Doan, email: ndoan@mcw.edu Keywords: pediatric glioblastoma, acid ceramidase inhibitors, carmofur, glioblastoma, medulloblastoma Received: September 12, 2016 Accepted: February 15, 2017 Published: March 01, 2017 ABSTRACT Pediatric brain tumors are the most common solid tumors in children and are also a leading culprit of cancer-related fatalities in children. Pediatric brain tumors remain hard to treat. In this study, we demonstrated that medulloblastoma, pediatric glioblastoma, and atypical teratoid rhabdoid tumors express significant levels of acid ceramidase, where levels are highest in the radioresistant tumors, suggesting that acid ceramidase may confer radioresistance. More importantly, we also showed that acid ceramidase inhibitors are highly effective at targeting these pediatric brain tumors with low IC 50 values (4.6–50 μM). This data suggests acid ceramidase as a novel drug target for adjuvant pediatric brain tumor therapies. Of these acid ceramidase inhibitors, carmofur has seen clinical use in Japan since 1981 for colorectal cancers and is a promising drug to undergo further animal studies and subsequently a clinical trial as a treatment for pediatric patients with brain tumors.
No takes yet. Share an insight, caveat, or question.
Doan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: